Premium
A case series of medication‐related fibrovascular hyperplasia following hematopoietic stem cell transplantation for Fanconi anemia
Author(s) -
Ballardin Bárbara Soldatelli,
Mobile Rafael Zancan,
Coracin Fábio Luiz,
Ribeiro Lisandro Lima,
Bonfim Carmem Maria Sales,
Schussel Juliana Lucena,
TorresPereira Cassius
Publication year - 2021
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.13947
Subject(s) - medicine , calcineurin , etiology , fanconi anemia , hematopoietic stem cell transplantation , hyperplasia , extramedullary hematopoiesis , transplantation , tacrolimus , dermatology , anemia , aplastic anemia , pathology , gastroenterology , stem cell , haematopoiesis , bone marrow , biochemistry , chemistry , genetics , biology , dna repair , gene
Abstract Systemic medications categorized as diphenylhydantoin, calcineurin inhibitor and calcium channel blocker may have effects on the oral cavity by modifying the inflammatory and immune response and causing undesired tissue proliferative reactions. Calcineurin inhibitors are medications commonly used for long periods in patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) and solid organ transplantation. Medication‐related fibrovascular hyperplasia (MRFH) is an extra gingival hyperplastic nodular growth associated with medications use. This study reports five cases of pediatric patients (6 to 12‐years‐old) diagnosed with Fanconi anemia (FA) after HSCT who presented similar oral mucosal lesions associated with the use of cyclosporine, phenobarbital and amlodipine. After excision of the lesions, histopathological analysis described them as pyogenic granuloma (PG). As the aetiology of the lesions manifested by the patients was associated with the use of medications, the final diagnosis was MRFH. Despite the clinical and histopathological similarity between PG and MRFH, it is fundamental to know the aetiological agent for achieving definitive diagnosis and correct management. Considering the etiologic agent (medication) and histopathological findings, it is suggested that the most appropriate term for this manifestation should be “medication‐related fibrovascular hyperplasia”. The correct nomenclature related to extra gingival hyperplastic lesions identified in patients on medications with potential to induce hyperplastic reactions should be adopted to facilitate scientific communication and improve the treatment.